title: [Aortic reconstruction with graft materials resistant to bacterial infections].
abstract: Synthetic graft infection is a rare but extremely serious complication of aortic reconstruction procedures, with morbidity-mortality rates as high as 60 %. Some of the proteins (albumin, gelatin, collagen) used to coat polyester graft materials can establish ionic bonds with antibiotics or can capture antiseptics such as triclosan or ionic silver in their matrices. These active substances are then released from the graft, at varying rates, during the coating degradation that takes place during the weeks following polyester graft implantation in living tissues. Rifampin-bonded prostheses have proved effective against S. aureus and S. epidermidis in several canine models of synthetic aortic graft infection. Rifampin-bonded grafts have also been used successfully in patients with synthetic aortic graft infection by low-virulence bacteria. However, their effectiveness may be limited by the diverse and changing ecology of synthetic aortic graft infections, with an increasing prevalence of multidrug-resistant bacteria and polymicrobial infections. These include species that are naturally, or are likely to become, resistant to rifampin. We evaluated silver-ion-bonded prostheses in this setting but observed a disappointingly high mid-term rate of recurrent infections. Over the past few years we have been involved in the development of polyester vascular prostheses functionalized with a hydroxypropyl-β-cyclodextrin polymeric matrix that can capture and elute several therapeutic agents. The results are promising, as these prostheses enable the sustained release of various antibiotics in amounts several times their minimum inhibitory concentrations. This provides a unique opportunity to functionalize materials for aortic graft reconstruction, based on epidemiological data or individual bacteriological findings.
authors.forename: Réda
authors.initials: R
authors.lastname: Hassen-Khodja
authors.forename: Nirvana
authors.initials: N
authors.lastname: Sadaghianloo
authors.forename: Élixène
authors.initials: É
authors.lastname: Jean-Baptiste
mesh_terms: D000085:Acetates / Q000008:administration & dosage; D000418:Albumins; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D000891:Anti-Infective Agents, Local / Q000008:administration & dosage*; D001011:Aorta / Q000601:surgery*; D001672:Biocompatible Materials; D001807:Blood Vessel Prosthesis / Q000382:microbiology; D019917:Blood Vessel Prosthesis Implantation; D020099:Coated Materials, Biocompatible; D003094:Collagen; D003505:Cyclodextrins / Q000008:administration & dosage; D004285:Dogs; D024901:Drug Resistance, Multiple, Bacterial; D005780:Gelatin; D006801:Humans; D008422:Materials Testing; D011108:Polymers; D016459:Prosthesis-Related Infections / Q000382:microbiology / Q000517:prevention & control*; D012293:Rifampin / Q000008:administration & dosage; D018030:Silver Compounds / Q000008:administration & dosage
chemical_list: D000085:Acetates; D000418:Albumins; D000900:Anti-Bacterial Agents; D000891:Anti-Infective Agents, Local; D001672:Biocompatible Materials; D020099:Coated Materials, Biocompatible; D003505:Cyclodextrins; D011108:Polymers; D018030:Silver Compounds; C103100:silver acetate; D005780:Gelatin; D003094:Collagen; D012293:Rifampin